Herbalife has signed an agreement to acquire certain assets from Bioniq, a UK-based personalised supplements business.
The purchase is intended to broaden Herbalife’s capabilities in customised nutrition and support its aim to develop into a technology-enabled, data-driven health and wellness platform.
Under the terms disclosed, the transaction carries a $55m purchase price to be paid across five years, beginning with $10m at closing.
The deal also includes up to $95m in additional contingent payments tied to future performance.
Bioniq builds individualised supplement formulas using what it describes as a patented personalisation engine, alongside a person’s health background and its own biomarkers database.
The company’s formulations target a wide set of users, ranging from general wellness consumers to professional athletes, including Cristiano Ronaldo.
Ronaldo, described as a long-standing global nutrition partner of Herbalife, is a Bioniq shareholder.
Herbalife said Bioniq would add to its earlier acquisitions of Pro2col and Link BioSciences, allowing it to offer more personalised nutritional supplements in multiple delivery formats.
The company also stated that pairing Bioniq’s offering with Herbalife’s global manufacturing capabilities would help it scale personalised nutrition more quickly.
Herbalife CEO Stephan Gratziani said: “The future of health and wellness is becoming more personalised and informed by data. By combining Bioniq’s personalised supplement technology with Pro2col and the power of our global distributor network, we are expanding our ability to deliver personalised wellness at global scale.”
Bioniq founder and president Vadim Fedotov said : “I founded Bioniq in 2019 with a vision to help people optimise their wellbeing through a science-driven approach to nutrition that incorporates biomarker and lifestyle data.
“I am excited to join Herbalife with its global distributor network and commitment to advancing wellness at scale.”
The companies expect the transaction to complete in the second quarter of 2026, subject to standard closing conditions and regulatory clearance.
As part of the agreement, Herbalife has also secured a call option to acquire Bioniq LAB, a separate platform focused on small molecules and peptides.
Herbalife said the option would give it flexibility to assess longer-term opportunities in that area.
Bioniq’s personalised nutritional supplements are expected to be made available later this year via Herbalife’s independent distributors for customers in selected European countries and the US, with further markets planned thereafter.
